Date:11/13/2009

me tax (provision) benefit (73,150) 51,878 ------- ------ Net income (loss) $68,625 $(138,951) ======= ========= Net income (loss) per diluted share $.01 $(.01) ==== ===== Balance Sheet Highlights September 30, June 30, 2009 2009 ---- ---- Cash $385,153 $141,714 Accounts receivable 4,818,809 4,739,727 Inventories 6,312,906 6,199,251 Total current assets 12,389,266 12,003,068 Total assets 17,412,796 17,087,289 Accounts payable 1,843,377 1,795,520 Accrued expenses 462,980 446,327 Line of credit 5,027,943 4,602,651 Total current liabilities 8,122,750 7,785,881 Total liabilities 10,918,387 10,667,540 Total liabilities and equity $17,412,796 $17,087,289

Dynatronics manufactures, markets and distributes advanced-technology medical devices, orthopedic soft goods and supplies, treatment tables and rehabilitation equipment for the physical therapy, sports medicine, chiropractic, podiatry, plastic surgery, dermatology and other related medical, cosmetic and aesthetic markets. More information regarding Dynatronics is available at www.dynatronics.com.

This press release contains forward-looking statements. Those statements include references to the co
'/>"/>

SOURCE Dynatronics Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Dynatronics Appoints Douglas Sampson as Vice President of Production and Research & Development
2. Dynatronics Will Request Hearing With Nasdaq Regarding Listing Status
3. Dynatronics to Release First Quarter Results Friday, November 13, 2009; Conference Call Set for 1:30 p.m. ET
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results